Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bicarbonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 5/20 | 0.50 |
| ▸ | CA1 | P00915 | 4/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LDHA | P00338 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL7762411 | 0.95 | CA1 (0.56) | CA4CA1CA2CA9FAHD1 | |
| Bicarbonate SCHEMBL1919132 | 0.95 | CA1 (0.56) | CA4CA1CA2CA9FAHD1 | |
| Bicarbonate SCHEMBL9512094 | 0.95 | CA1 (0.56) | CA4CA1CA2CA9FAHD1 | |
| Bicarbonate SCHEMBL18042414 | 0.95 | CA1 (0.56) | CA4CA1CA2CA9FAHD1 | |
| Bicarbonate SCHEMBL17309684 | 0.95 | CA1 (0.56) | CA4CA1CA2CA9FAHD1 | |
| Bicarbonate SCHEMBL6168589 | 0.95 | CA1 (0.56) | CA4CA1CA2CA9FAHD1 | |
| Bicarbonate SCHEMBL4760182 | 0.95 | CA1 (0.56) | CA4CA1CA2CA9FAHD1 | |
| Bicarbonate SCHEMBL9010920 | 0.95 | CA1 (0.56) | CA4CA1CA2CA9FAHD1 | |
| Bicarbonate SCHEMBL163255 | 0.95 | CA1 (0.56) | CA4CA1CA2CA9FAHD1 | |
| Bicarbonate SCHEMBL14763676 | 0.95 | CA1 (0.56) | CA4CA1CA2CA9FAHD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121574370-A | Polyimide resin with high light transmittance and preparation method thereof | 安徽三旺化学有限公司 | 2026-02-27 | — | — | CN | claimed |
| CN-118851931-A | Ratio type probe for detecting activity of butyrylcholine esterase as well as preparation method and application thereof | 商丘师范学院 | 2024-10-29 | — | — | CN | claimed |
| CN-114989189-B | Compound with aggregation-induced emission performance, and preparation method and application thereof | 西南交通大学 | 2023-09-26 | — | — | CN | claimed |
| CN-114989189-A | Compound with aggregation-induced emission performance and preparation method and application thereof | 西南交通大学 | 2022-09-02 | — | — | CN | claimed |
| CN-111303139-A | Compound with aggregation-induced emission performance and preparation method and application thereof | 西南交通大学 | 2020-06-19 | — | — | CN | claimed |
| US-8946479-B2 | Process for preparation of 4-fluoro-α-[2methyl-l-oxopropyl]-γ-oxo—N—β-diphenylbenzene butane amide | VIJAYASRI ORGANICS LIMITED (IN) | 2015-02-03 | — | — | US | claimed |
| EP-0959881-B1 | SYNTHETIC METHODS FOR THE PREPARATION OF INDOLYLQUINONES AND MONO- AND BIS-INDOLYLQUINONES PREPARED THEREFROM | SUGEN INC (US) | 2005-09-21 | — | — | EP | claimed |
| US-20030060635-A1 | Methods of using bis-indolylquinones | TANG PENG C (US) | 2003-03-27 | — | — | US | claimed |
| EP-0959881-A4 | SYNTHETIC METHODS FOR THE PREPARATION OF INDOLYLQUINONES AND MONO- AND BIS-INDOLYLQUINONES PREPARED THEREFROM | SUGEN INC (US) | 2001-06-27 | — | — | EP | claimed |
| EP-0959881-A1 | SYNTHETIC METHODS FOR THE PREPARATION OF INDOLYLQUINONES AND MONO- AND BIS-INDOLYLQUINONES PREPARED THEREFROM | Sugen, Inc. (US) | 1999-12-01 | — | — | EP | claimed |
| US-5786488-A | DEHYDROBROMINATION OF A DIBROMOBENZOQUINONES WITH AT LEAST ONE INDOLES IN A POLAR SOLVENT AND A METAL CARBONATE TO FORM AN ANTITUMOR AGENT | SUGEN, INC. (US) | 1998-07-28 | — | — | US | claimed |
| WO-1998020874-A1 | SYNTHETIC METHODS FOR THE PREPARATION OF INDOLYLQUINONES AND MONO- AND BIS-INDOLYLQUINONES PREPARED THEREFROM | SUGEN, INC. (US) | 1998-05-22 | — | — | WO | claimed |
| EP-4680239-A2 | SIGMA-1 RECEPTOR ANTAGONISTS AND THEIR APPLICATIONS | Humanwell Pharmaceutical US, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| CN-118851931-A | Ratio type probe for detecting activity of butyrylcholine esterase as well as preparation method and application thereof | 商丘师范学院 | 2024-10-29 | — | — | CN | disclosed |
| US-20240317745-A1 | SIGMA-1 RECEPTOR ANTAGONISTS AND THEIR APPLICATIONS | YICHANG HUMANWELL PHARMACEUTICALS CO., LTD. (CN) | 2024-09-26 | — | — | US | disclosed |
| WO-2024192247-A2 | SIGMA-1 RECEPTOR ANTAGONISTS AND THEIR APPLICATIONS | HUMANWELL PHARMACUETICAL US, INC. (US) | 2024-09-19 | — | — | WO | disclosed |
| EP-1213290-B1 | DIHYDROBENZOFURAN DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND AGENTS | TAKEDA PHARMACEUTICAL (JP) | 2005-04-20 | — | — | EP | disclosed |
| CN-1518534-A | Copper-catalyzed carbon-heteroatom and carbon-carbon bond formation | 麻省理工学院 | 2004-08-04 | — | — | CN | disclosed |
| EP-1259489-A1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | Pfizer Products Inc. (US) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001062736-A1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060635-A1 | Methods of using bis-indolylquinones | IDO2, IDO1, IPO5 | CA4 164/4885CA1 483/4885CA2 29/4885 |
| US-20240317745-A1 | SIGMA-1 RECEPTOR ANTAGONISTS AND THEIR APPLICATIONS | SIGMAR1, OPRK1, OPRL1 | CA4 4869/4885CA1 4816/4885CA2 4281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.